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Abstract
The landmark papers published by Judah Folkman in the early 1970s on tumor angiogenesis and therapeutic implications
promoted the rapid development of a very dynamic ﬁeld where basic scientists, oncologists, and pharmaceutical industry joined
forces to determine the molecular mechanisms in blood vessel formation and ﬁnd means to exploit this knowledge in
suppressing tumor vascularization and growth. A wealth of information has been collected on angiogenic growth factors, and in
2004 the ﬁrst speciﬁc blood vessel-targeted cancer therapy was introduced: a neutralizing antibody against vascular endothelial
growth factor (VEGF). Now (2011) we know that suppression of tumor angiogenesis may be a double-edged sword and that
the therapy needs to be further reﬁned and individualized. This review describes the hallmarks of tumor vessels, how different
angiogenic growth factors exert their function, and the perspectives for future development of anti-angiogenic therapy.
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Blood vessels in health and disease
Blood is carried by a hierarchical network of vessels
lined by a single layer of endothelial cells (EC).
Circulation of blood allows delivery of oxygen to
the tissues (1), which is essential for the generation
of energy by the mitochondria. Nutrients are taken up
by the blood passing through thin-walled capillaries in
the intestinal tract, and storage of nutrients and
detoxiﬁcation of the blood are mediated by hepatic
and renal circulation, respectively. The ECs deposit a
basement membrane composed of ﬁbronectin, colla-
gen IV, laminins, and heparan sulfate proteoglycans
(HSPG) (2), which directly or indirectly inﬂuences
diverse processes such as cell differentiation, attach-
ment, migration, polarization, guidance, and survival.
Vessels are surrounded by smooth muscle cells in a
manner dependent on their size and position vis-à-vis
the heart; arteries display a muscular coat that reg-
ulates the vascular tone, whereas capillaries are more
sparsely supported by specialized mesenchymal cells
denoted pericytes.
Formation of new vessels, angiogenesis, is critical in
growing tissues. The principles of blood vessel for-
mation differ dependent on whether blood vessels
form during embryogenesis (denoted vasculogenesis),
during physiological processes such as wound healing
or growth of the endometrium (denoted regulated
angiogenesis), or during pathologies such as inﬂam-
mation and cancer (denoted pathological, or dysre-
gulated angiogenesis). In addition, vessels may form
through splitting, in a process called intussusception
(3), or may be derived from circulating, bone-
marrow-derived progenitors (denoted adult or post-
natal vasculogenesis) (4).
Several features distinguish vessels formed during
physiological processes from those in pathologies such
as cancer. Healthy vessels are arranged in a hierar-
chical manner (arteries, capillaries, and veins),
whereas the tumor vasculature is disorganized
and morphologically abnormal. Healthy vessels are
moreover perfused, whereas tumor vessels display
partial or complete occlusions leading to poor blood
ﬂow (5). Pericytes, which depend on production of
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cells, embed healthy capillaries. In contrast, tumor
vessels often have a scarce coat of loosely associated
pericytes (6). Moreover, the vascular basement mem-
brane may be discontinuous. Tumor vessels are leaky,
in part due to the deﬁcient perivascular support, but
also due to abundant expression of vascular endothe-
lial growth factor (VEGF), also denoted vascular
permeability factor (VPF), or inﬂammatory cytokines
in the growing tumor (5). The leakiness leads to a
build-up of interstitial pressure and impaired drug
delivery. The edema may in itself aggravate the con-
dition e.g. for patients suffering from brain tumors
such as glioblastoma multiforme. Production of other
growth factors such as ﬁbroblast growth factor (FGF)
by tumor cells may furtherpromote excess growth and
dysregulation of the vasculature. Thus, a number of
growth factors exert their effect in the tumor micro-
environment in a manner that promotes progression
of the disease (Figure 1).
Growth factors in regulation of blood vessel
formation
Growth factors are major stimulators of angiogene-
sis. A large number of second messengers may
modulate, positively or negatively, their downstream
effect. Studies on gene-targeted animals have been
instrumental in deducing the role of different growth
factors, especially during embryonic development.
Below, I will discuss the features of a number of
key angiogenic growth factors.
Vascular endothelial growth factors (VEGFs)/vascular
permeability factor (VPF)
Ligands. VEGF denotes a family of ﬁve structurally
related mammalian ligands: VEGFA, VEGFB,
VEGFC, VEGFD, and placental growth factor
(PlGF). VEGF was originally identiﬁed as vascular
permeability factor (VPF) (7). The VEGFs are com-
posed of covalently linked homodimers (8), but there
are also naturally occurring heterodimers, e.g. of
VEGFA and PlGF (9). Alternative splicing and pro-
cessing generate further diversity. Related polypep-
tides from other species include the VEGFEs, which
are open reading frame(s) in parapoxvirus, and the
VEGFFs, found in snake venom. VEGFA is up-
regulated in hypoxia, as shown originally by Eli
Keshet and co-workers (10).
Receptors. VEGF ligands bind to three related receptor
tyrosine kinases, denoted VEGFR1, VEGFR2, and
VEGFR3. VEGFA, VEGFB, and PlGF bind to
VEGFR1. VEGFA, VEGFC, and VEGFD bind
to VEGFR2; and VEGFC and VEGFD bind to
VEGFR3. In cells coexpressing VEGFR2 and
VEGFR3, VEGFC and VEGFD will induce hetero-
dimers of the receptors. VEGFRs show a similar
organization with an extracellular, ligand-binding
domain composed of seven immunoglobulin (Ig)-like
loops, a transmembrane domain, a juxtamembrane
domain, a split tyrosine kinase domain, and a
C-terminal tail (Figure 2). There is an overall pattern
of VEGFR1 expression in monocytes and macro-
phages, VEGFR2 in vascular endothelial cells, and
VEGFR3 in lymphatic endothelial cells. However,
clearly the expression of the receptors is dynamic,
and, for example, VEGFR3 is expressed in vascular
endothelial cells engaged in active angiogenesis (11).
Whereas ECs in the stable vasculature weakly express
VEGFR2, the receptor is up-regulated and expressed
at high levels during physiological or pathological
angiogenesis (e.g. in tumors) (12).
VEGFs also bind to a range of accessory molecules,
which occasionally are denoted VEGF receptors.
These include heparan sulfate proteoglycans
(HSPGs)/heparin, the neuropilins, and integrins
(13). As these molecules are devoid of intrinsic
catalytic activity, it is more appropriate to use the
designation ‘VEGF co-receptor’. The VEGF co-
receptors are essential for VEGF biology and direct
the cellular response in a fundamental way. Thus,
HSPGs and the mast cell-secreted heparin bind
growth factors in a charge-dependent manner and
mediate efﬁcient presentation to the cognate receptor.
HSPGs may also bind directly to the receptor such
as VEGFR2 (14). By creating local growth factor
gradients, HSPGs provide guidance cues for new
vessels. Neuropilins (neuropilin1 and neuropilin2),
bind semaphorins, axon-guidance molecules, and
VEGF family members to non-overlapping extra-
cellular domains (15). NRP1 regulates VEGF-
induced vessel sprouting and branching. Moreover,
NRP1 binds to the adaptor GIPC/synectin and
thereby directs VEGFR2 internalization. Integrins
engage in complex formation with VEGF receptors
and direct downstream signaling and endothelial
migration.
Lessons from genetic models. Gene targeting of VEGFA
and VEGFR2 results in similar phenotypes with arrest
in EC differentiation and embryonic death around
embryonic day E8.5. Clearly, VEGFA/VEGFR2
function is a strict prerequisite for EC development,
EC survival, and for regulation of vascular permeabi-
lity in the adult (13).
In contrast to VEGFA, elimination of either
VEGFB or PlGF is compatible with embryonic deve-
lopment. Interestingly, the ligands for VEGFR1 have
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speciﬁc role in revascularization of the ischemic myo-
cardium (16) and, importantly, in fatty acid transport
over the endothelium to the target tissue (17). In
contrast, PlGF has been more generally implicated
in regulation of pathological angiogenesis. Thus,
PlGF-deﬁcient animals develop normally, but, due
to a reduced angiogenic response, tumor growth and
inﬂammatory processes are attenuated (18). Gene
targeting of VEGFR1, which binds VEGFA, VEGFB,
and PlGF, leads to embryonic death around E9.5, due
to excess proliferation of EC and poor organization of
cells to form lumenized vessels (19). It is noteworthy
that VEGFR1 is produced not only as a full-
length receptor but also as a soluble extracellular
domain. This soluble form binds VEGFA with high
afﬁnity and has been suggested to serve as a trap,
immobilizing VEGFA and preventing it from binding
to VEGFR2 (20). As mice expressing a truncated
VEGFR1, lacking the intracellular tyrosine kinase
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Figure 1. Production of VEGF, FGF, and PDGF in the tumor microenvironment. VEGF is produced by most cells in the tumor
microenvironment, including endothelial cells and macrophages. It exerts its effects on endothelial cells; occasionally, tumor cells may
express VEGF receptors and respond to VEGF. PDGF is produced by endothelial cells and serves to attract pericytes to embed the newly
formed vessel; however, in the tumor, pericytes as a rule fail to wrap tightly around the endothelial cells. FGF is produced by tumors cells and
may act directly on tumor vessels but not on endothelial cells in healthy tissues.
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Figure 2. Properties of VEGF, FGF, and PDGF receptors and their signaling. Schematic outline of receptors is shown. All three VEGF
receptors are organized into an extracellular domain with seven Ig-like folds and a short kinase insert. Tyrosine phosphorylation sites have been
identiﬁed at some positions. Key features of VEGFR2 signaling are the binding of the adaptor molecule TSAd to the kinase insert
phosphorylation site Y951 and regulation of Src activation followed by opening of adherens junctions. A C-terminal phosphorylation site
at Y1175 allows binding of PLCg and signaling in the Erk pathway. FGF receptors are composed of three Ig-like loops extracellularly, a very
short kinase insert, and signaling via FRS2, which associates to the FGFR without involvement of tyrosine phosphorylation sites. PLCg is an
important downstream signal transducer in FGF biology. PDGF receptors have ﬁve extracellular Ig-like loops and a long kinase insert. The
PDGF receptors become phosphorylated at very many tyrosine residues in response to ligand binding and induce formation of several
long signaling chains. Erk = extracellular regulated kinase; FRS2 = FGF receptor substrate 2; P = phosphate; PLCg=phospholipase Cg;
TSAd = T cell speciﬁc adaptor.
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survive embryogenesis, it appears that VEGFR1
signaling is not required per se for endothelial cell
development. However, the VEGFR1 extracellular
domain serves to bind VEGF and to negatively
regulate VEGFR2 activity. The mechanism whereby
the three ligands for VEGFR1, VEGFA, VEGFB,
and PlGF, exert their different biological effects is
unclear but could involve differential binding to
additional receptors or co-receptors, such as the
neuropilins (15).
VEGFC and VEGFD bind to VEGFR3. VEGFC
gene inactivation results in disruption of lymphatic
vessel development and prenatal death due to tissue
ﬂuid accumulation (21). VEGFD gene targeting, on
the other hand, is compatible with normal mouse
development (22). Knock-out of VEGFR3 leads to
a distinct phenotype consisting of cardiovascular fail-
ure and embryonic death at E9.5 (23). VEGFR3 is
expressed in tip cells of sprouting vessels, in agree-
ment with an important role for VEGFR3 in angio-
genesis (11). VEGFC as well as VEGFR3 have been
implicated in induction of tumor angiogenesis and
lymphangiogenesis (24). Integrins can induce Src-
dependent phosphorylation of VEGFR3 and down-
stream signaling independently of VEGFC/VEGFD
and activation of the VEGFR3 kinase (25).
VEGFR signaling. VEGFR tyrosine phosphorylation
patterns have been described in vitro (26-28), and the
in-vivo validation for certain of these sites has been
initiated (29). VEGFRs share many signaling path-
ways with most if not all receptor tyrosine kinases,
such as the phospholipase Cg (PLCg) pathway reg-
ulating proliferation of endothelial cells through the
extracellular regulated kinase (ERK) pathway and
the phosphoinositide 3’ kinase (PI3K)/AKT path-
way. For VEGFR2, which is the most studied
VEGFR this far, the following features stand out:
1) Ras activation may not be induced in response to
VEGF; instead induction of proliferation is depen-
dent on PLCg/ERK. In agreement with this notion, a
tyrosine-to-phenylalanine knock-in at Y1173, the
VEGFR2 phosphorylation site that binds PLCg,
leads to embryonic death and endothelial cell deﬁ-
ciency (29). 2) VEGFR2 activates endothelial nitric
oxide synthase (eNOS) which is important in regu-
lation of vascular permeability (30). Another poten-
tial pathway in regulation of vascular permeability
involves the VEGFR2 phosphorylation site Y949,
which binds the adaptor molecule T cell-speciﬁc
adaptor, which in turn promotes activation of Src,
allowing regulation of endothelial junctions (28).
For a comprehensive review on VEGFR signaling,
see Koch et al. (13).
Diseases and therapies. VEGFA production is enhan-
ced in hypoxia and is therefore found in growing
tissues such as cancer. Although VEGF is not a
biomarker in cancer, it is expressed by most, if not
all, forms of human tumor disease. A recent focus has
been on inﬂammatory cells, which inﬁltrate the tumor
and may constitute most of the tumor mass. Inﬂam-
matory cells are important in delivery of angiogenic
growth factors, such as VEGF, to the tumor (31).
A critical question is whether VEGFRs are expressed
not only on tumor endothelial cells but also on the
tumor cells, where VEGFR regulation and signaling
may be distinct from that in endothelial cells. Therapy
strategies developed this far are, however, based on
neutralizing antibodies or kinase inhibitors and inde-
pendent of the expression pattern of VEGFs and
VEGFRs (32). Clinically more pressing questions
are instead those of side-effects and refractoriness/
resistance to treatment, as discussed below.
In 1993, Kim et al. showed that a neutralizing
antibody against mouse VEGF (A.4.6.1) inhibited
tumor growth and angiogenesis in mouse models
(33). The positive results obtained with A.4.6.1 led
to the development of a humanized version of this
antibody, bevacizumab (Avastin), providing one of
the most successful marketed compounds within the
anti-angiogenic therapy ﬁeld.
DC-101, a monoclonal antibody that targets
murine VEGFR2, efﬁciently blocks tumor growth
in a variety of tumor xenograft models as well as
hepatic metastasis derived from colon cancer
(34,35). Fully humanized anti-VEGFR2 antibodies
were developed for subsequent clinical use, such as
IMC-1121B (ramucirumab). Studies performed with
this antibody have demonstrated its efﬁcient anti-
tumor effects in murine xenograft models (36,37).
Several tyrosine kinase inhibitors (TKIs) that
inhibit VEGFR2 have been tested in preclinical stu-
dies. Sunitinib (Sutent; Pﬁzer), sorafenib (Nexavar;
Bayer), and pazopanib (Votrient; GlaxoSmithKline)
are the most advanced drugs within this group.
Fibroblast growth factors (FGFs)
Ligands. The FGF family encompasses 22 proteins
(FGF1–23) identiﬁed to date (38). FGF2 is a potent
mitogen for endothelial cells in vitro; it was the ﬁrst
angiogenic growth factor to be identiﬁed (39). FGFs
have several distinguishing features. Thus, although
most FGFs are secreted, the prototypic FGF1 (acidic
FGF) and FGF2 (basic FGF) lack a signal sequence
typical for secreted proteins. The mechanism
for secretion of FGF1 and FGF2 has remained con-
troversial, although several mechanisms have been
suggested, such as direct translocation across the
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proteins (40). Alternatively, FGF1 and FGF2 become
released upon cell death. Furthermore, certain FGF
variants are taken up and brought to the nucleus,
where they may play a role in regulation of proli-
feration (41).
Receptors. There are four FGF receptor tyrosine
kinases (FGFR1–4) with a very similar molecular
organization of three extracellular Ig-like loops, a
transmembrane domain, and a split tyrosine kinase
domain (Figure 2). The extracellular FGFR domains
undergo extensive alternative splicing, which regu-
lates ligand binding. There is a certain degree of
tissue-speciﬁc expression of the different splice
variants, which is matched by the tissue-speciﬁc
expression of the corresponding ligand. However,
FGF1 will bind all FGFR isoforms (see (42) for a
comprehensive review).
FGFs bind with very high afﬁnity to HSPGs, which
are known to act as co-receptors for the FGFRs (43).
FGFs have also been reported to bind to neuropilins,
but the details of the binding motifs and the biological
consequence remain to be described.
Lessons from genetic models. A challenge in deciphering
the biology of FGFRs has been their low expression
levels, typically around 1,000 molecules/cell. Whether
any of the FGFRs indeed are expressed in endothelial
cells in vivo, possibly in speciﬁc organs or in particular
processes, has been difﬁcult to determine. Gene tar-
geting efforts have established that FGFs/FGFRs have
essential roles during development and in a wide
spectrum of physiological processes such as skeletal
development (44). In contrast, accumulating data
have not supported the notion that FGFs/FGFRs
act directly on EC in vivo. That FGFRs are expressed
on endothelial cells in vitro and that FGF2 is a strong
mitogen for endothelial cells in culture are well estab-
lished. FGFs/FGFRs may still be very important for
vessel biology in vivo, e.g. by regulating expression of
cytokines that in turn may affect vessel function. For
example, FGFR1-deﬁcient embryonic stem cells
show an exaggerated tendency to form EC, due to
a FGFR1-dependent change in expression of cyto-
kines such as interleukin-4 and pleiotrophin (45).
Furthermore, FGFs act directly on EC in pathologies
such as cancer where FGFRs may become up-regu-
lated (46) (see below).
FGFR signaling. FGFRs are ﬁrst and foremost asso-
ciated with cell proliferation. The adaptor protein
FRS2 (FGFR substrate 2) acts as a hub linking several
signaling pathways to the activated FGFRs (42).
FRS2 binds to the juxtamembrane region of FGFR,
and upon activation of the receptor it becomes phos-
phorylated on several tyrosine residues, creating dock-
ing sites for additional adaptor proteins, including the
Ras/ERK pathway and the PI3K/AKT pathway.
Diseases and therapies. Elevated levels in serum of
FGFs and FGFRs have been described in many forms
of human cancer, including brain cancer, head and
neck cancer, gastric cancer, ovarian cancer, and bone
cancer. The spectrum of target cells for the ensuing
activities is likely to be broad, including endothelial
cells.
Several TKIs that inhibit FGFRs are tested in early-
phase clinical trials; none of these is speciﬁc for
FGFRs, and often also VEGFRs and PDGFRs are
targeted. Novel more speciﬁc FGFR inhibitors are
being developed at present, such as AZD4547 and
BGJ398 (see http://ClinicalTrials.gov).
Platelet-derived growth factors (PDGFs)
Ligands. PDGFs, which are structurally related to
VEGFs, occur as covalently linked homo- or hetero-
dimers. There are ﬁve dimeric PDGF isoforms,
assembled from polypeptide chains denoted A,
B, C, and D (i.e. PDGF-AA, PDGF-BB, PDGF-
AB, PDGF-CC and PDGF-DD) (47). The A and B
forms are secreted as active forms, whereas the C and
D forms are produced as inactive forms containing
CUB-domains which must be removed to allow
receptor binding (47). The different PDGFs are
produced by a variety of epithelial cells.
Receptors. PDGFs interact withtwo structurally related
receptor tyrosine kinases, denoted PDGFRa and
PDGFRb,whichmayhomo-orheterodimerizedepend-
ing on the ligand. The receptors are structurally highly
related, with ﬁve Ig-like extracellular loops, and a split
tyrosine kinase domain (Figure 2). Both receptor types
areexpressedon mesenchymalcells(48).Interestingly,
PDGFRb expression is regulated by inﬂammation.
Thus, ﬁbroblasts in healthy tissues do not express
PDGFRb, whereas ﬁbroblasts in tissues involved in
inﬂammatory processes such as rheumatoid arthritis
express the receptor, as do cultured ﬁbroblasts (49).
PDGFA and B forms bind HSPGs/heparin, but
with relatively low afﬁnity (50). Integrins are critical
modulators of PDGFR signaling, and adhesion of
cells to speciﬁc extracellular matrix may activate
PDGFRs in the absence of a ligand (51).
Lessons from genetic models. Overall, PDGF has impor-
tant roles during development in particular of
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wound healing and regulates interstitial pressure (48).
Different PDGFs and receptors have been studied
by gene inactivation in different combinations.
PDGFA deﬁciency gives rise to lung emphysema
due to a defect in alveolar smooth muscle cells
(52). Mice with PDGFC-deﬁciency die at birth due
to respiratory failure and cleft palate, which impairs
suckling (53). Combined deletion of PDGFA and
PDGFC genes has effects resembling those seen in
mice lacking PDGFRa (54). Inactivation of PDGFD
does not result in a phenotype in unchallenged mice
(personal communication, Professor Ulf Eriksson,
Karolinska Institute, Sweden). None of these genes
directly affect endothelial cell biology. Gene inactiva-
tion of PDGFB and PDGFRb (55–57), on the other
hand, gives rise to very similar phenotypes, with loss
of mesangial cells in the kidney and close to complete
loss of pericyte formation. Loss of pericyte formation
results in a weakened vessel wall and hemorrhaging,
resulting in perinatal death.
PDGFR signaling. PDGFRb was one of the ﬁrst
receptor tyrosine kinases to be studied in detail, by
mapping of phosphorylation sites and identiﬁcation
of Src Homology 2 (SH2) domain proteins and other
signal transducers binding speciﬁcally to the different
sites. There is therefore detailed information on the
pathways induced, which include all major known
signaling pathways such as the PLCg/PKC, PI3K/
AKT, and Ras/MAPK pathways. A similar pattern
exists for PDGFRa (48).
Interestingly,PDGFRsignalingmaybemodulatedby
VEGF.ItwasrecentlysuggestedthattheeffectofPDGF
on pericytes is negatively regulated by VEGF through
formation of VEGFR2/PDGFRb complexes (58).
Diseases and therapies. PDGF over-activity has been
linked to tumor progression as well as to atheroscle-
rosis and ﬁbrotic conditions, and it is clear that PDGF
signaling may contribute to multiple tumor-
promoting processes. Moreover, gene rearrange-
ments, mutation, and ampliﬁcation of PDGF or
PDGFR family members have been linked to rela-
tively rare forms of cancer such as gastrointestinal
stromal tumors (48).
Tumor vessels often show incomplete pericyte cov-
erage, which at least in part contributes to the poor
functionality of the tumor vasculature, with poor per-
fusion, leakiness, and turnover. Moreover, PDGFRb
expressed on stromal ﬁbroblasts regulates interstitial
ﬂuid pressure, which is elevated in tumors, interfering
with efﬁcient uptake of drugs (59). Expression of
PDGFRb on tumor pericytes has allowed targeting
of pericytes in cancer therapy, and preclinical analyses
have indicated that combined anti-VEGF and anti-
PDGF therapy may be beneﬁcial (60).
The role of VEGF, FGF, and PDGF in
refractoriness to anti-angiogenic treatment
Despite the successes of benchmark therapies like
Avastin/bevacizumab (anti-VEGF antibodies), not
all patients beneﬁt from treatment. In some patients,
tumors shrink only to grow again, and the clinical
beneﬁt is usually measured in months, not years.
A number of phase III clinical trials have shown no
beneﬁt (61). Moreover, in preclinical models, sup-
pression of VEGF has been associated with more
aggressive disease and increased metastatic spread
(62,63). Several mechanisms have been brought for-
ward to explain the refractoriness to anti-angiogenic
treatment (64), as outlined below. A consistent theme
is the plasticity of the tumor.
Advanced disease
With progressive disease, the sensitivity to anti-
angiogenic therapy diminishes (65). There may be
no response, or an initial response followed by
relapsed disease. Advanced cancer may have reached
a state where a wide range of growth stimuli overlap in
their promoting effects on different cellular constitu-
ents. Moreover, the tumor cells have undergone a
number of mutations and chromosomal rearrange-
ments, further aggravating the disease.
Alternative mechanisms in blood vessel formation
Blood vessels may form through several mechanisms
that may be differently regulated (see above). Whereas
a wealth of data implicate sprouting angiogenesis in
tumor vascularization, intussusception, co-option,
and vasculogenic mimicry may also be involved.
Formation of vascular channels lined by cancer
stem cell-derived endothelial cells has been shown,
e.g. in glioblastoma (66).
Production of angiogenic growth factors and endothelial
cell plasticity
With time and in a situation where VEGF or VEGFRs
are inhibited, endothelial cells may acquire the capac-
ity to respond to other, compensatory growth factors
such as FGF2, stromal derived factor 1 (SDF1),
ephrins, angiopoietins, and PDGFB and PDGFC
(67–69). These growth factors may be produced by
tumor cells, by bone-marrow-derived cells (BMDCs),
tumor-associated macrophages (TAMs), or tumor-
associated ﬁbroblasts (70). For example, treatment of
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resulted in an initial decrease in vascularity followed
by vascular rebound and in an increase in expression
of FGFs (67). Increased levels of circulating
FGF2 have also been noted in human patients
treated with AZD2171, a pan-VEGFR2 tyrosine
kinase inhibitor (71). PlGF was also reported to be
increased in the circulation following treatment with
sunitinib (72).
Epigenetic and genetic mechanisms in resistance
Genetic and/or epigenetic patterns in tumor endothe-
lial cells are unstable and change after anti-
angiogenic treatment (73,74). The original concept
that endothelial cells are ‘normal’ and derived from
healthy vessels that are stimulated by production of
VEGF in the tumor is probably only partially correct.
For example, endothelial cells in healthy tissues do
not express receptors for epidermal growth factor
(EGF); however, in cancer forms that express EGF,
such as prostate cancer, EGFR is expressed on tumor
endothelial cells (75).
Is anti-angiogenic therapy a viable long-
term prospect in cancer treatment?
Although the introduction of anti-VEGF therapy in
cancer was coined a breakthrough, and many patients
have had clear beneﬁts of the treatment, there is more
to do to optimize both the treatment itself (dose, time-
frame, combination with chemotherapy). It has also
become clear that while large cohorts of patients with
advanced disease may not beneﬁt from the treatment,
there are groups of individuals for whom this treat-
ment is very important. Two major lines of efforts are
important in the future development of anti-
angiogenic therapy.
Preclinical studies versus human disease
Tumor models in mice lack most of the characteris-
tics typically found in human disease. Preclinical
studies are predominantly performed with tumors
that grow in the avascular subcutaneous compart-
ment. Here, tumors have to induce angiogenesis in
order to grow, thus being more susceptible to anti-
angiogenic therapy. In human cancer, however,
tumors often grow in highly vascularized tissues,
where growth not only depends on angiogenesis but
also on vessel co-optation, thus increasing resistance
to anti-angiogenic compounds. Moreover, for most
tumor models in mice, the disease is acute, whereas in
humans, it arises slowly over the course of many years
or decades. Finally, in mice, the study is interrupted
due to ethical concerns based on the properties of the
primary tumor irrespective of metastatic spread. In
humans, it is the metastatic spread that presents the
major threat. Characteristics that clearly distinguish
metastases from primary tumors have been very dif-
ﬁcult to deﬁne, due to the molecular heterogeneity of
the metastatic lesions. It is also unclear if hematogenic
and lymphatic spread of tumors should be differently
treated or targeted. The standard for tumor models
has to be clearly deﬁned in order to be relevant for
human disease.
Early treatment and identiﬁcation of biomarkers
VEGF inhibition in preclinical models is accompa-
nied by a window of vessel normalization, which may
facilitate for example delivery of chemotherapy. To
exploit this aspect in the treatment of human cancer,
current imaging and non-invasive markers of matu-
ration must be further developed. Moreover, combi-
natorial therapy with chemotherapeutic agents needs
further reﬁnement, since chronic angiogenesis
inhibition reduces tumor uptake of co-administered
chemotherapy. Overall, based on the collected expe-
rience, improved strategies for clinical trials need to
be developed. Efﬁcient anti-angiogenic therapy for
human cancer requires biomarkers to select respon-
ders within the patient cohorts. Clearly, efﬁcient anti-
angiogenic responsiveness depends on the stage of
tumor development and on the tumor microenviron-
ment. Individualized therapy will be a key to future
successful development of cancer therapy.
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